Vetoquinol

Q3 2020 Sales: €114.5 Million* (up 14.3%) - Seite 2

* Unaudited data

Vetoquinol CEO Matthieu Frechin said: “I am proud of the work done by our teams during the first nine months of 2020. Despite the adverse impact of this exceptional and unprecedented health crisis, we have succeeded in continuing the roll-out of our strategic plan, underpinned by the strength of our Essentials product portfolio, acquisitions, expense-management initiatives and the unflagging commitment shown by our employees. The acquisition of the Profender and Drontal products has enabled us to reach a major milestone in the execution of our strategy, with their initial integration into our Essentials portfolio going ahead according to plan. We are all working together to achieve our growth ambitions for 2020 and the forthcoming period.”

€m

2020

2019

Change
(reported
data)

Change
(constant
exchange
rates)

Change
(LFL)

Q1 Sales - total

103.4

90.9

+13.7%

+13.4%

+10.5%

Q2 Sales - total

92.7

92.9

-0.2%

+1.8%

+4.6%

Q3 Sales - total

114.5

100.1

+14.3%

+18.9%

+17.2%

Aggregate 9-month sales

310.6

283.9

+9.4%

+11.5%

+10.7%

Next update: 2020 Annual Sales - January 21, 2021 after market close.

About Vetoquinol
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At June 30^th 2020, Vetoquinol employs 2,401 people.